klacid xl tablet
abbott laboratories s.a. (pty) ltd - tablet - see ingredients - each tablet contains clarithromycin 500,0 mg
klacid 500mg coated tab coated tablet
abbott laboratories, united kingdom - clarithromycin - coated tablet - 500 mg
atripla
gilead sciences (nz) - efavirenz 600mg; ; ; ; emtricitabine 200mg; ; ; ; tenofovir disoproxil fumarate 300mg; ; ; - film coated tablet - active: efavirenz 600mg emtricitabine 200mg tenofovir disoproxil fumarate 300mg excipient: croscarmellose sodium hyprolose magnesium stearate microcrystalline cellulose opadry pink 85f94172 purified water sodium laurilsulfate - atripla is indicated for the treatment of hiv infected adults over the age of 18 years, alone or in combination with other antiretroviral agents.
klacid 250 milligram tablets
b & s healthcare - clarithromycin - tablets - 250 milligram
klacid 250 milligram tablets
g & a licensing limited - clarithromycin - tablets - 250 milligram
klacid tablet 500mg
abbott laboratories (m) sdn. bhd. - clarithromycin -
klacid hp7
abbott australasia pty ltd - clarithromycin; omeprazole; amoxycillin -
klacid la 500mg modified release tablets
mylan ire healthcare limited - clarithromycin - modified-release tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections caused by susceptible organisms. indications include: lower respiratory tract infections for example bronchitis and pneumonia. upper respiratory tract infections for example sinusitis and pharyngitis. skin and soft tissue infections for example folliculitis, cellulitis and erysipelas.
klacid la 500mg modified release tablets
viatris healthcare limited - clarithromycin - modified-release tablet - macrolides; clarithromycin
klacid tablets 250 milligram
b & s healthcare - clarithromycin - tablets - 250 milligram